Raw Ground Truth
Inclusion Criteria:Diagnosed with RRMS per revised McDonald criteria (2017) with an EDSS score ≤ 6.5 at screeningNeurologically stable with no evidence of relapse within the 28 days before signing the informed consent form (ICF)Either not currently receiving disease modifying MS therapy, or currently using fumarate drugs (dimethyl fumarate or diroximel fumarate)Patients must use a highly effective method of birth control or are sterile or postmenopausal as confirmed by study InvestigatorPatient has signed and understands the ICFExclusion Criteria:Diagnosis of primary progressive MS or secondary progressive MSUncontrolled or significant medical conditions (including active infection or chronic hepatitis) which, in the opinion of the Investigator, preclude participationPatients treated with glatiramer acetate, parenteral steroids or adrenocorticotropic hormone, β-interferon, plasma exchange within the 3 months prior to first dosePatients treated with sphingosine-1-phospate receptor modulators such as fingolimod, ozanimod, or siponimod within 6 months prior to first dosePatients treated with cytotoxic agents (including, but not limited to, cladribine, mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod, teriflunomide, or IV gamma globulin within 12 months prior to first dosePatients treated with monoclonal antibody therapy (including natalizumab, daclizumab, rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dosePatients previously treated with alemtuzumab, total lymphoid irradiation, mesenchymal stem cell or hematopoietic stem cell transplantation, or tolerance-inducing therapies for MSContraindication to or inability to undergo gadolinium-enhanced magnetic resonance imaging (MRI) scanUse of any investigational drug or experimental procedure within previous 6 months that would interfere with the assessment of ANK-700Patients who are pregnant or breastfeedingPatients receiving any vaccination within 28 days prior to first dosePatient does not agree to limit alcohol intake to 2 drink equivalents or less per day during the study
Raw Prediction
### Revised Eligibility Criteria for Version 8 Clinical Trial
#### Original Eligibility Criteria (Version 7):
**Inclusion Criteria:**
- Diagnosed with RRMS per revised McDonald criteria (2017)
- With an EDSS score ≤ 6.5 at screening
- Neurologically stable with no evidence of relapse within the 28 days before signing the informed consent form (ICF)
**Exclusion Criteria:**
- Diagnosis of primary progressive MS or secondary progressive MS
- Uncontrolled or significant medical conditions (including active infection or chronic hepatitis)
- Which, in the opinion of the Investigator, preclude participation
- Treatment with glatiramer acetate, parenteral steroids, or adrenocorticotropic hormone, β-interferon, plasma exchange within the 3 months prior to first dose
- Treatment with sphingosine-1-phosphate receptor modulators such as fingolimod, ozanimod, or siponimod within 6 months prior to first dose
- Treatment with cytotoxic agents (including, but not limited to, cladribine, mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod, teriflunomide, or IV gamma globulin within 12 months prior to first dose
- Treatment with monoclonal antibody therapy (including natalizumab, daclizumab, rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dose
- Previous treatment with alemtuzumab, total lymphoid irradiation, mesenchymal stem cells or hematopoietic stem cells transplantation, or tolerance-inducing therapies for MS
#### Updated Eligibility Criteria (Version 8):
**Inclusion Criteria:**
- Male or female adults aged 18 to 60 years inclusive at screening
- Diagnosed with RRMS per revised McDonald criteria (2017) with an EDSS score ≤ 6.5 at screening
- Neurologically stable with no evidence of relapse within the 28 days prior to signing the informed consent form (ICF)
- Either not currently receiving disease modifying MS therapy, or currently using fumarate drugs (i.e., dimethyl fumarate, diroximel fumarate)
- Patients must use a highly effective method of birth control or are sterile or postmenopausal as confirmed by study investigator for the first 3 months (through D90) of the study
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has signed and understood the ICF
- Patient has
Processed Ground Truth
1. Diagnosed with RRMS per revised McDonald criteria (2017) with an EDSS score ≤ 6.5 at screeningNeurologically stable with no evidence of relapse within the 28 days before signing the informed consent form (ICF)Either not currently receiving disease modifying MS therapy, or currently using fumarate drugs (dimethyl fumarate or diroximel fumarate)Patients must use a highly effective method of birth control or are sterile or postmenopausal as confirmed by study InvestigatorPatient has signed and understands the ICFExclusion Criteria:Diagnosis of primary progressive MS or secondary progressive MSUncontrolled or significant medical conditions (including active infection or chronic hepatitis) which, in the opinion of the Investigator, preclude participationPatients treated with glatiramer acetate, parenteral steroids or adrenocorticotropic hormone, β-interferon, plasma exchange within the 3 months prior to first dosePatients treated with sphingosine-1-phospate receptor modulators such as fingolimod, ozanimod, or siponimod within 6 months prior to first dosePatients treated with cytotoxic agents (including, but not limited to, cladribine, mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod, teriflunomide, or IV gamma globulin within 12 months prior to first dosePatients treated with monoclonal antibody therapy (including natalizumab, daclizumab, rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dosePatients previously treated with alemtuzumab, total lymphoid irradiation, mesenchymal stem cell or hematopoietic stem cell transplantation, or tolerance-inducing therapies for MSContraindication to or inability to undergo gadolinium-enhanced magnetic resonance imaging (MRI) scanUse of any investigational drug or experimental procedure within previous 6 months that would interfere with the assessment of ANK-700Patients who are pregnant or breastfeedingPatients receiving any vaccination within 28 days prior to first dosePatient does not agree to limit alcohol intake to 2 drink equivalents or less per day during the study
Processed Prediction
1. Revised Eligibility Criteria for Version 8 Clinical Trial
2. Original Eligibility Criteria (Version 7):
1. Diagnosed with RRMS per revised McDonald criteria (2017)
2. With an EDSS score ≤ 6.5 at screening
3. Neurologically stable with no evidence of relapse within the 28 days before signing the informed consent form (ICF)
1. Diagnosis of primary progressive MS or secondary progressive MS
2. Uncontrolled or significant medical conditions (including active infection or chronic hepatitis)
3. Which, in the opinion of the Investigator, preclude participation
4. Treatment with glatiramer acetate, parenteral steroids, or adrenocorticotropic hormone, β-interferon, plasma exchange within the 3 months prior to first dose
5. Treatment with sphingosine-1-phosphate receptor modulators such as fingolimod, ozanimod, or siponimod within 6 months prior to first dose
6. Treatment with cytotoxic agents (including, but not limited to, cladribine, mitoxantrone, cyclophosphamide, azathioprine, and methotrexate), laquinimod, teriflunomide, or IV gamma globulin within 12 months prior to first dose
7. Treatment with monoclonal antibody therapy (including natalizumab, daclizumab, rituximab, ofatumumab, and ocrelizumab) within 24 months prior to first dose
8. Previous treatment with alemtuzumab, total lymphoid irradiation, mesenchymal stem cells or hematopoietic stem cells transplantation, or tolerance-inducing therapies for MS
9. Updated Eligibility Criteria (Version 8):
1. Male or female adults aged 18 to 60 years inclusive at screening
2. Diagnosed with RRMS per revised McDonald criteria (2017) with an EDSS score ≤ 6.5 at screening
3. Neurologically stable with no evidence of relapse within the 28 days prior to signing the informed consent form (ICF)
4. Either not currently receiving disease modifying MS therapy, or currently using fumarate drugs (i.e., dimethyl fumarate, diroximel fumarate)
5. Patients must use a highly effective method of birth control or are sterile or postmenopausal as confirmed by study investigator for the first 3 months (through D90) of the study
6. Patient has signed and understood the ICF
7. Patient has signed and understood the ICF
8. Patient has signed and understood the ICF
9. Patient has signed and understood the ICF
10. Patient has signed and understood the ICF
11. Patient has signed and understood the ICF
12. Patient has signed and understood the ICF
13. Patient has signed and understood the ICF
14. Patient has signed and understood the ICF
15. Patient has signed and understood the ICF
16. Patient has signed and understood the ICF
17. Patient has signed and understood the ICF
18. Patient has signed and understood the ICF
19. Patient has signed and understood the ICF
20. Patient has signed and understood the ICF
21. Patient has signed and understood the ICF
22. Patient has signed and understood the ICF
23. Patient has signed and understood the ICF
24. Patient has signed and understood the ICF
25. Patient has signed and understood the ICF
26. Patient has signed and understood the ICF
27. Patient has signed and understood the ICF
28. Patient has signed and understood the ICF
29. Patient has signed and understood the ICF
30. Patient has signed and understood the ICF
31. Patient has signed and understood the ICF
32. Patient has signed and understood the ICF
33. Patient has signed and understood the ICF
34. Patient has signed and understood the ICF
35. Patient has signed and understood the ICF
36. Patient has signed and understood the ICF
37. Patient has signed and understood the ICF
38. Patient has signed and understood the ICF
39. Patient has signed and understood the ICF
40. Patient has signed and understood the ICF
41. Patient has signed and understood the ICF
42. Patient has signed and understood the ICF
43. Patient has signed and understood the ICF
44. Patient has signed and understood the ICF
45. Patient has signed and understood the ICF
46. Patient has signed and understood the ICF
47. Patient has signed and understood the ICF
48. Patient has signed and understood the ICF
49. Patient has signed and understood the ICF
50. Patient has signed and understood the ICF
51. Patient has signed and understood the ICF
52. Patient has signed and understood the ICF
53. Patient has signed and understood the ICF
54. Patient has signed and understood the ICF
55. Patient has signed and understood the ICF
56. Patient has signed and understood the ICF
57. Patient has signed and understood the ICF
58. Patient has signed and understood the ICF
59. Patient has signed and understood the ICF
60. Patient has signed and understood the ICF
61. Patient has signed and understood the ICF
62. Patient has signed and understood the ICF
63. Patient has signed and understood the ICF
64. Patient has signed and understood the ICF
65. Patient has signed and understood the ICF
66. Patient has signed and understood the ICF
67. Patient has signed and understood the ICF
68. Patient has signed and understood the ICF
69. Patient has signed and understood the ICF
70. Patient has signed and understood the ICF
71. Patient has signed and understood the ICF
72. Patient has signed and understood the ICF
73. Patient has signed and understood the ICF
74. Patient has signed and understood the ICF
75. Patient has signed and understood the ICF
76. Patient has signed and understood the ICF
77. Patient has signed and understood the ICF
78. Patient has signed and understood the ICF
79. Patient has signed and understood the ICF
80. Patient has signed and understood the ICF
81. Patient has signed and understood the ICF
82. Patient has signed and understood the ICF
83. Patient has signed and understood the ICF
84. Patient has signed and understood the ICF
85. Patient has signed and understood the ICF
86. Patient has signed and understood the ICF
87. Patient has signed and understood the ICF
88. Patient has signed and understood the ICF
89. Patient has signed and understood the ICF
90. Patient has signed and understood the ICF
91. Patient has signed and understood the ICF
92. Patient has signed and understood the ICF
93. Patient has signed and understood the ICF
94. Patient has signed and understood the ICF
95. Patient has signed and understood the ICF
96. Patient has signed and understood the ICF
97. Patient has signed and understood the ICF
98. Patient has signed and understood the ICF
99. Patient has signed and understood the ICF
100. Patient has signed and understood the ICF
101. Patient has signed and understood the ICF
102. Patient has signed and understood the ICF
103. Patient has signed and understood the ICF
104. Patient has signed and understood the ICF
105. Patient has signed and understood the ICF
106. Patient has signed and understood the ICF
107. Patient has signed and understood the ICF
108. Patient has signed and understood the ICF
109. Patient has signed and understood the ICF
110. Patient has signed and understood the ICF
111. Patient has signed and understood the ICF
112. Patient has signed and understood the ICF
113. Patient has signed and understood the ICF
114. Patient has signed and understood the ICF
115. Patient has signed and understood the ICF
116. Patient has signed and understood the ICF
117. Patient has signed and understood the ICF
118. Patient has signed and understood the ICF
119. Patient has signed and understood the ICF
120. Patient has signed and understood the ICF
121. Patient has signed and understood the ICF
122. Patient has signed and understood the ICF
123. Patient has signed and understood the ICF
124. Patient has signed and understood the ICF
125. Patient has signed and understood the ICF
126. Patient has signed and understood the ICF
127. Patient has signed and understood the ICF
128. Patient has signed and understood the ICF
129. Patient has signed and understood the ICF
130. Patient has signed and understood the ICF
131. Patient has signed and understood the ICF
132. Patient has signed and understood the ICF
133. Patient has signed and understood the ICF
134. Patient has signed and understood the ICF
135. Patient has signed and understood the ICF
136. Patient has signed and understood the ICF
137. Patient has signed and understood the ICF
138. Patient has signed and understood the ICF
139. Patient has signed and understood the ICF
140. Patient has signed and understood the ICF
141. Patient has signed and understood the ICF
142. Patient has signed and understood the ICF
143. Patient has signed and understood the ICF
144. Patient has signed and understood the ICF
145. Patient has signed and understood the ICF
146. Patient has signed and understood the ICF
147. Patient has signed and understood the ICF
148. Patient has signed and understood the ICF
149. Patient has signed and understood the ICF
150. Patient has signed and understood the ICF
151. Patient has signed and understood the ICF
152. Patient has signed and understood the ICF
153. Patient has signed and understood the ICF
154. Patient has signed and understood the ICF
155. Patient has signed and understood the ICF
156. Patient has signed and understood the ICF
157. Patient has